| Identification | Back Directory | [Name]
MC-VC-PAB-MMAF | [CAS]
863971-17-9 | [Synonyms]
Mc-VC-MMAF
MC-VC-PAB-MMAF
Val-Cit-PAB-MMAF
Benzoicacid,3,4,7-tris(phenylmethoxy)-
2-[[3-[1-[4-[[2-[[2-[[4-[[5-(Carbamoylamino)-2-[[2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonyl
(2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl
L-Phenylalanine, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-
(2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid | [Molecular Formula]
C68H103N11O16 | [MOL File]
863971-17-9.mol | [Molecular Weight]
1330.61 |
| Chemical Properties | Back Directory | [Boiling point ]
1377.2±65.0 °C(Predicted) | [density ]
1.213±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.56±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
FLQSNYUAYBTJGF-VOTJHACZNA-N |
| Hazard Information | Back Directory | [Uses]
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity[1]. | [IC 50]
Auristatin | [References]
[1] Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675. DOI:10.1158/1535-7163.MCT-17-1215 |
|
| Company Name: |
Cool Pharm, Ltd
|
| Tel: |
021-58581007 18019463053 |
| Website: |
http://www.coolpharm.com.cn |
|